Last Price | 0.22 | Max Price | 0.22 |
Min Price | 0.22 | 1 Year return | -93.55 |
Avg. Target | 0.00 | Expected Return | -100.00 % |
Sector | Health Care | Subsector | Pharmaceuticals |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 0 | ||
Annual report 2017 |
Contact info:Street: Rue Saint-Georges 5Postbox: 4000City: LuikCountry: BelgiumPhone: +32 (0)4 349 28 22Email: investorrelations@mithra.com.Website: www.mithra.com
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 97 | 615,670 | 0.02 % |
2020 | 9 | 638,104 | 0.00 % |
2021 | 23 | 727,997 | 0.00 % |
2022 | 67 | 787,317 | 0.01 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Mithra, the stock lost around 10 percent. Mithra' stock lost the past 5 years at around 0 percent.
The global pharmaceutical companies gained around 75 percent worldwide over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.
The Belgian company didn't pay out any dividends (in the past 5 years).
At the end of 2015 the Belgian company had a balance sheet of around 156,83 million euros. At the end of 2015 the total debt positon equaled 26,29 million euros. This is around 16,76 percent of the total balance sheet.
The pharmaceutical company's market capitalization (the number of shares outstanding times the market value) equaled around 259,14 million euros. At the end of 2015 the Belgian company had around 25,41 million stocks listed.
All Mithra's financial reports are located here. More information about Mithra can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
20
|
22
|
46
|
58
|
97
|
9
|
Costs |
30
|
58
|
81
|
70
|
123
|
101
|
Profit |
-10
|
-35
|
-35
|
-12
|
-27
|
-92
|
Margin of profit |
-48.04
|
-156.16
|
-75.70
|
-21.35
|
-27.52
|
-1019.82
|
ROI |
-7.71
|
-37.72
|
-40.30
|
-8.19
|
-16.26
|
-58.38
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
127
|
93
|
87
|
151
|
163
|
158
|
Debt |
78
|
80
|
158
|
209
|
234
|
364
|
Total assets |
206
|
173
|
245
|
360
|
398
|
522
|
Solvency |
61.96
|
53.86
|
35.50
|
41.95
|
41.07
|
30.22
|
Cash |
97
|
46
|
36
|
123
|
50
|
139
|
Cashflow |
-18
|
-23
|
-31
|
4
|
-47
|
-80
|
Employees |
66
|
80
|
104
|
0
|
0
|
|
Revenue per employee |
0.31
|
0.28
|
0.44
|
0.0
|
0.0
|
|
Cashflow / Debt |
-0.23
|
-0.29
|
-0.20
|
0.02
|
-0.20
|
-0.22
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
10.20
|
9.04
|
10.26
|
20.00
|
26.26
|
Eps |
-1.13
|
-1.07
|
-0.34
|
-0.70
|
-2.25
|
Price/earnings-ratio |
-9.03
|
-8.45
|
-30.18
|
-28.57
|
-0.10
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
2.99
|
2.48
|
4.01
|
4.17
|
3.69
|
Market to book |
0.29
|
0.27
|
0.39
|
0.21
|
16.79
|
Cashflow per stock |
-0.75
|
-0.89
|
0.09
|
-1.20
|
-1.87
|
Stocks |
31
|
35
|
38
|
39
|
43
|
Market Cap |
317.52
|
316.10
|
386.18
|
782.66
|
9.40
|
Date
|
Price
|
---|---|
09 May 2025
|
0.22
|
01 May 2025
|
0.22
|
29 Apr 2025
|
0.22
|
22 Apr 2025
|
0.22
|
09 Apr 2025
|
0.22
|
08 Apr 2025
|
0.22
|
03 Apr 2025
|
0.22
|
30 Mar 2025
|
0.22
|
27 Mar 2025
|
0.22
|
26 Mar 2025
|
0.22
|
20 Mar 2025
|
0.22
|
15 Mar 2025
|
0.22
|
12 Mar 2025
|
0.22
|
01 Mar 2025
|
0.22
|
25 Feb 2025
|
0.22
|
23 Feb 2025
|
0.22
|
18 Feb 2025
|
0.22
|
13 Feb 2025
|
0.22
|
12 Feb 2025
|
0.22
|
07 Feb 2025
|
0.22
|
05 Feb 2025
|
0.22
|
02 Feb 2025
|
0.22
|
21 Jan 2025
|
0.22
|
17 Jan 2025
|
0.22
|
09 Jan 2025
|
0.22
|
17 Dec 2024
|
0.22
|
10 Dec 2024
|
0.22
|
06 Dec 2024
|
0.22
|
03 Dec 2024
|
0.22
|
29 Nov 2024
|
0.22
|